The Argatroban and tissue-type plasminogen activator stroke study: Final results of a pilot safety study

摘要

Developing new interventions for hyperacute stroke remains an important aim because current treatment options remain limited to alteplase, aspirin, hemicraniectomy, and stroke unit care. Over the last 20 years, drug developments have largely focused on fibrinolytic, neuroprotective, and anticoagulant strategies. Although the first is proven, the second and third remain without definitive data, although clinical research continues, as highlighted in the linked article by Baretto and colleagues who describe results from a small Phase II study of argatroban, an intravenous anticoagulant.